ReviewFrontiers in pharmacology2021
Influence of
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis.PloS one · 2025Pooled it
- Trial
- Comparative Effectiveness of Vonoprazan Dosing Strategies in Bismuth-Based Quadruple Therapy for Helicobacter pylori Eradication: A Prospective Non-inferiority Cohort Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Comparative efficacy and safety of vonoprazan versus esomeprazole-based high-dose dual therapies for first-lineTherapeutic advances in gastroenterology · 2025Article
- The efficacy and safety of Vonoprazan and Tegoprazan inTherapeutic advances in gastroenterology · 2025Article
- Crises in Antimicrobial Stewardship: Misuse of Clarithromycin forPharmacoepidemiology · 2024Article
- Helicobacter pylori Eradication Treatment in Older Patients.Drugs & aging · 2024Review
- Treatment ofHeliyon · 2023Review
- Helicobacter pylori infection.Nature reviews. Disease primers · 2023Review
- In Search for Reasons behindJournal of fungi (Basel, Switzerland) · 2023Article
- OvercomingActa pharmaceutica Sinica. B · 2022Review
- Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.